A
Abrocitinib
Availability of ACE Drug Guidance
Yes
Biologics Drug Information Overview
No
Post-marketing information
Dear Healthcare Professional Letters
Subsidy Information and Financing Scheme
Medical Assistance Fund
Active ingredient: Abrocitinib
General information
Subsidy Information and Financing Scheme
[MAF] Abrocitinib Tablet 50 mg, 100 mg, 200 mg
Additional clinical criteria applies
Treatment of moderate to severe atopic dermatitis (AD)
Drug Guidance for Subsidy
02/01/2024 Abrocitinib, baricitinib, upadacitinib and dupilumab for treating atopic dermatitis
The Ministry of Health’s Drug Advisory Committee has recommended:
Abrocitinib 50 mg, 100 mg and 200 mg film-coated tablets for treating moderate-to-severe atopic dermatitis in patients who have had an inadequate response, intolerance or contraindication to at least one systemic therapy such as ciclosporin, methotrexate, azathioprine and mycophenolate mofetil.
Funding status
[R] Abrocitinib 50 mg, 100 mg and 200 mg film-coated tablets are recommended for inclusion on the MOH Medication Assistance Fund (MAF) for the abovementioned indication from 1 March 2024.
[R] Abrocitinib should be used in line with additional clinical criteria for initial and continuing prescriptions for patients with moderate-to-severe atopic dermatitis.
[NR] MAF assistance does not apply to any formulations or strengths of baricitinib, upadacitinib or dupilumab for treating atopic dermatitis.
Post Marketing Information
General Availability in Public Healthcare Institution
Note:
General availability information reflected is based on the Public Healthcare Institutions’ (PHI) formulary on what is commonly used for treating their patient population and may or may not be available for patients not under the care of that institution. It does not reflect the PHI’s actual inventory availability and is subjected to change. Please consult the Public Hospitals or Polyclinics for details on availability and supply restrictions/considerations. General availability is not tied to any brand unless otherwise stated.
Users are to consult the respective PHIs for actual inventory availability and supply restrictions/consideration
Availability information
Formulation | Public Healthcare Institution |
|---|---|
Tablet 50 mg |
|
Tablet 100 mg |
|
Tablet 200 mg |
|
Registered Product(s) Information
Clinical and product info
Clinical info | Product Info |
|---|---|
Information under the Indication, Dosage and Contraindication sections are extracted from the relevant Package Insert/Patient Information Leaflet of the product available on HSA Infosearch. For more information, please refer to the product's Package Insert/ Patient Information Leaflet available on HSA Infosearch. The information provided is for informational purposes only, and is not exhaustive. The information provided is not a substitute for professional medical advice. Please consult a qualified healthcare provider for any medical advice. | Information available here are product details as registered with the HSA. As this website is updated monthly, please refer to HSA Infosearch for the most updated product information. |
Oral
* Clinical information is available for this product.